Next Article in Journal
OpenDrop: An Integrated Do-It-Yourself Platform for Personal Use of Biochips
Next Article in Special Issue
In Vitro Evaluation of Glycoengineered RSV-F in the Human Artificial Lymph Node Reactor
Previous Article in Journal
In Vitro Growth of Human Keratinocytes and Oral Cancer Cells into Microtissues: An Aerosol-Based Microencapsulation Technique
Previous Article in Special Issue
Human Cell Line-Derived Monoclonal IgA Antibodies for Cancer Immunotherapy
Open AccessArticle

Comparative N-Glycosylation Analysis of the Fc Portions of a Chimeric Human Coagulation Factor VIII and Immunoglobulin G1

Octapharma Biopharmaceuticals GmbH, Molecular Biochemistry, Walther-Nernst-Strasse 3, 12489 Berlin, Germany
Author to whom correspondence should be addressed.
Academic Editors: Stephan Hinderlich and Hans Henning von Horsten
Bioengineering 2017, 4(2), 44;
Received: 13 April 2017 / Revised: 10 May 2017 / Accepted: 11 May 2017 / Published: 17 May 2017
(This article belongs to the Special Issue Recombinant Glycoproteins)
Prevention and treatment of bleeding in patients suffering from hemophilia A are inconvenient due to repeated intravenous infusions owing to the short half-life of coagulation factor VIII (FVIII) in circulation. Besides (glyco-)pegylation of the FVIII molecule, a bioengineering approach comprises the protein fusion to Fc-immunoglobulin (Ig)G that mediate protection from clearance or degradation via binding to the neonatal Fc receptor. While human-like N-glycosylation of recombinant FVIII is known to be crucial for the clotting factor’s quality and function, the particular glycosylation of the fused Fc portion has not been investigated in detail so far, despite its known impact on Fcγ receptor binding. Here, we analyzed the N-glycosylation of the Fc part of a chimeric FVIII-Fc protein compared to a commercial IgG1 purified from human plasma. Fc parts from both samples were released by enzymatic cleavage and were subsequently separated via sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Corresponding protein bands were referred to PNGase F in-gel digestion in order to release the respective N-glycans. Analysis via matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry revealed structural differences of both N-glycan patterns. Labeling with 2-aminobenzamide (2AB) and analysis via hydrophilic interaction liquid chromatography (HILIC) allowed a quantitative comparison of the respective N-glycosylation. Observed variations in Fc glycosylation of the chimeric FVIII fusion protein and human plasma-derived IgG1, e.g., regarding terminal sialylation, are discussed, focusing on the impact of the clotting factor’s properties, most notably its binding to Fcγ receptors. View Full-Text
Keywords: Fc-fusion; immunoglobulin G; immunomodulation; N-glycosylation; recombinant FVIII Fc-fusion; immunoglobulin G; immunomodulation; N-glycosylation; recombinant FVIII
Show Figures

Figure 1

MDPI and ACS Style

Kannicht, C.; Kröning, M.; Solecka-Witulska, B.A.; Kohla, G.; Rosenlöcher, J. Comparative N-Glycosylation Analysis of the Fc Portions of a Chimeric Human Coagulation Factor VIII and Immunoglobulin G1. Bioengineering 2017, 4, 44.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop